Prediction of Postoperative Recurrence in Crohn's Disease
Prediction Model and Molecular Mechanisms of Postoperative Recurrence in Crohn's Disease
This multicenter prospective observational cohort study aims to develop and validate a multimodal prediction model for postoperative recurrence in patients with Crohn's disease.
Patients with Crohn's disease who undergo intestinal resection will be enrolled and followed after surgery. Residual surgical tissue that would otherwise be discarded, together with routinely collected clinical data and biological samples, will be used for research. Multi-omics analyses, including single-cell transcriptomics and spatial transcriptomics, will be performed to identify biological features associated with postoperative recurrence.
Participants with Crohn's disease will be followed for clinical, endoscopic, and imaging recurrence after surgery. The study will use data from a screening cohort to develop a prediction model and a validation cohort to evaluate the performance of the model. A control group consisting of patients undergoing intestinal resection for conditions such as colorectal tumors or diverticular disease will also be included for comparative molecular analyses.
No treatment will be assigned by the study protocol. All treatment decisions will be made by the treating physicians according to routine clinical practice.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Crohn's disease is characterized by chronic relapsing intestinal inflammation, and a substantial proportion of patients eventually require intestinal resection because of complications such as strictures, penetrating disease, or failure of medical therapy. Postoperative recurrence remains common, but reliable biomarkers and validated prediction models for identifying patients at high risk of recurrence are still lacking.
This is a multicenter, prospective, observational cohort study designed to investigate the predictors and molecular mechanisms of postoperative recurrence in Crohn's disease. The study consists of a screening cohort and a validation cohort. Approximately 200 patients with Crohn's disease undergoing intestinal resection will be enrolled, including 100 participants in the screening cohort and 100 participants in the validation cohort. In addition, approximately 50 patients undergoing intestinal resection for colorectal tumors, diverticular disease, or other non-inflammatory bowel disease conditions will be enrolled as controls.
In the screening cohort, residual surgical specimens that would otherwise be discarded will be collected. Clinical characteristics, follow-up information, biological samples, and multi-omics data will also be collected. Molecular profiling will include analyses such as bulk transcriptomics, single-cell transcriptomics, spatial transcriptomics, proteomics, microbiome analysis, and metabolomics, as applicable. Differences between patients with and without postoperative recurrence will be evaluated, and machine-learning methods will be used to construct a multimodal prediction model.
The validation cohort will be used to evaluate the predictive performance of the multimodal model in a multicenter setting. Postoperative recurrence will be assessed using clinical, endoscopic, and imaging evaluations during follow-up. The study also aims to investigate molecular pathways associated with postoperative recurrence and to identify potential therapeutic targets.
This study is observational. No randomized assignment or protocol-mandated treatment will be provided. Clinical management and postoperative treatment decisions will be made independently by the treating physicians according to routine clinical practice.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Xiang Gao, MD
- Número de telefone: +86-13502405878
- E-mail: gxiang@mail.sysu.edu.cn
Locais de estudo
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510655
- Recrutamento
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contato:
- Xiang Gao, MD
- Número de telefone: +86-13502405878
- E-mail: gxiang@mail.sysu.edu.cn
-
Contato:
- E-mail: guoq83@mail.sysu.edu.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
Crohn's Disease Cohorts:
- Diagnosis of Crohn's disease according to the diagnostic criteria of the Chinese Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing).
- Patients with Crohn's disease who require surgical resection of the diseased intestinal segment because of complications such as stricturing or penetrating disease, or because of failure of medical therapy.
Non-IBD Control Cohort:
1.Patients who require surgical resection of an intestinal segment because of conditions such as colorectal tumors or diverticular disease.
Exclusion Criteria:
Crohn's Disease Cohorts:
- Uncertain diagnosis of Crohn's disease.
- Clinical history or medical records are substantially incomplete, making it impossible to determine the time of recurrence or whether postoperative recurrence occurred.
Non-IBD Control Cohort:
- Coexisting inflammatory bowel disease or other rheumatic or autoimmune diseases.
- Substantially incomplete clinical history or medical records.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Screening Cohort
Patients with Crohn's disease undergoing clinically indicated intestinal resection.
Approximately 100 participants will be enrolled in this cohort.
Residual surgical tissue, clinical characteristics, biological samples, and multi-omics data will be collected.
Participants will be followed after surgery to identify clinical, endoscopic, and imaging recurrence.
Data from this cohort will be used to identify molecular features associated with postoperative recurrence and to develop a multimodal prediction model.
|
Participants undergo intestinal resection as clinically indicated as part of routine medical care.
The surgical procedure is not assigned by the study protocol.
Residual surgical tissue that would otherwise be discarded may be collected for research analyses.
Residual surgical tissue and biological samples are collected for research.
Surgical tissue used for research consists of residual specimens remaining after routine clinical pathological examination.
Samples may be used for transcriptomic, single-cell transcriptomic, spatial transcriptomic, proteomic, microbiome, metabolomic, and other multi-omics analyses.
|
|
Validation Cohort
Patients with Crohn's disease undergoing clinically indicated intestinal resection.
Approximately 100 participants will be enrolled in this multicenter validation cohort and followed after surgery.
Clinical, endoscopic, imaging, and biological data will be collected to evaluate the predictive performance of the multimodal model developed in the screening cohort.
|
Participants undergo intestinal resection as clinically indicated as part of routine medical care.
The surgical procedure is not assigned by the study protocol.
Residual surgical tissue that would otherwise be discarded may be collected for research analyses.
Residual surgical tissue and biological samples are collected for research.
Surgical tissue used for research consists of residual specimens remaining after routine clinical pathological examination.
Samples may be used for transcriptomic, single-cell transcriptomic, spatial transcriptomic, proteomic, microbiome, metabolomic, and other multi-omics analyses.
|
|
Non-IBD Control Cohort
Patients without inflammatory bowel disease who undergo clinically indicated intestinal resection for conditions such as colorectal tumors or diverticular disease.
Approximately 50 participants will be enrolled.
Residual surgical tissue that would otherwise be discarded will be collected for comparative molecular and multi-omics analyses.
|
Participants undergo intestinal resection as clinically indicated as part of routine medical care.
The surgical procedure is not assigned by the study protocol.
Residual surgical tissue that would otherwise be discarded may be collected for research analyses.
Residual surgical tissue and biological samples are collected for research.
Surgical tissue used for research consists of residual specimens remaining after routine clinical pathological examination.
Samples may be used for transcriptomic, single-cell transcriptomic, spatial transcriptomic, proteomic, microbiome, metabolomic, and other multi-omics analyses.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical Recurrence Rate at 6 Months
Prazo: 6 months after intestinal resection
|
Clinical recurrence is defined as the recurrence of clinical manifestations or complications such as abdominal pain, diarrhea, hematochezia, fistula, or perforation, together with a Harvey-Bradshaw Index (HBI) >4 or Crohn's Disease Activity Index (CDAI) >150, with recurrence confirmed by endoscopic or imaging assessment.
The outcome is reported as the proportion of participants with clinical recurrence.
|
6 months after intestinal resection
|
|
Endoscopic Recurrence Rate at 6 Months
Prazo: 6 months after intestinal resection
|
Endoscopic recurrence is defined as a Rutgeerts score of i2 or higher on postoperative endoscopy after complete resection of macroscopically diseased bowel.
The outcome is reported as the proportion of participants meeting the criterion for endoscopic recurrence.
|
6 months after intestinal resection
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Endoscopic Recurrence Rate at 1 Year
Prazo: 1 year after intestinal resection
|
Endoscopic recurrence is defined as a Rutgeerts score of i2 or higher on postoperative endoscopy after complete resection of macroscopically diseased bowel.
The outcome is reported as the proportion of participants meeting the criterion for endoscopic recurrence.
|
1 year after intestinal resection
|
|
Clinical Recurrence Rate at 1 Year
Prazo: 1 year after intestinal resection
|
Clinical recurrence is defined as recurrence of clinical manifestations or complications such as abdominal pain, diarrhea, hematochezia, fistula, or perforation, together with a Harvey-Bradshaw Index (HBI) >4 or Crohn's Disease Activity Index (CDAI) >150, with recurrence confirmed by endoscopic or imaging assessment.
The outcome is reported as the proportion of participants with clinical recurrence.
|
1 year after intestinal resection
|
|
Imaging Recurrence Rate at 1 Year
Prazo: 1 year after intestinal resection
|
Imaging recurrence is defined as a score of 2 or higher on computed tomography enterography (CTE) or magnetic resonance enterography (MRE) after surgical resection of the diseased bowel.
The outcome is reported as the proportion of participants meeting the imaging recurrence criterion.
|
1 year after intestinal resection
|
|
Imaging Recurrence Rate at 6 Months
Prazo: 6 months after intestinal resection
|
Imaging recurrence is defined as a score of 2 or higher on computed tomography enterography (CTE) or magnetic resonance enterography (MRE) after surgical resection of the diseased bowel.
The outcome is reported as the proportion of participants meeting the imaging recurrence criterion.
|
6 months after intestinal resection
|
|
Reoperation or Endoscopic Treatment Rate at 1 Year
Prazo: 1 year after intestinal resection
|
The outcome is defined as the proportion of participants who require repeat intestinal resection or endoscopic treatment because of Crohn's disease recurrence after the index intestinal resection.
Stoma reversal procedures and surgeries for perianal disease are not counted as outcome events.
|
1 year after intestinal resection
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- G2025005
- 2025ZSLYEC-290 (Outro identificador: Ethics Committee of The Sixth Affiliated Hospital, Sun Yat-sen University)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .